Thread: Role of alpha-synuclein, PARP and PAR in the death of neurons (via parthanatos) in PD
View Single Post
Old 11-12-2018, 09:00 PM
Tupelo3 Tupelo3 is offline
Member
  
Join Date: Mar 2013
Location: New Jersey
Posts: 832
10 yr Member
Tupelo3 Tupelo3 is offline
Member
 
Join Date: Mar 2013
Location: New Jersey
Posts: 832
10 yr Member
Default
Quote:
Originally Posted by jeffreyn View Post
For those not put off already by the title, Simon does a great job of explaining another piece of the PD puzzle, via the following SoPD blog post:

We’re re-branding: It’s now called PARPinson’s | The Science of Parkinson's

The comment section of this SoPD blog post is also well worth a read. The following link is to an article referred to by Patrik Brundin in one of those comments:

Science Magazine - November 2, 2�18
Niraparib (zejula) was selected for funding at the most recent Linked Clinical Trials meeting (funding for repurposed drugs). It’s a really effective parp1 inhibitor. It was clearly the most interesting presentation, though a few others were also exciting. Look for announcement of a clinical trial to begin in 2019.
Tupelo3 is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
eds195 (11-21-2018), jeffreyn (11-13-2018)